Dr. Lukas Hartl of the Vienna Liver Study Groups demonstrated that in cirrhosis there are Renin-Angiotensin-System (RAS)-associated alterations in systemic inflammation and the coagulation profile (i.e. without an infection) – and this molecular profile is similar to patients without liver disease who develop mild COVID-19.
In turn, these cirrhosis-associated abnormalities in the RAS-Inflammation-Coagulation axis explain why cirrhotic patients are at particular risk for a severe course of COVID-19 infection (where we observed the highest levels of RAS-Inflammation-Coagulation Dysregulation.
Check out the full article in the Journal of Personalized Medicine (JPM) 2021: